Kalaris Therapeutics, Inc.(KLRS)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
KLRS Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Kalaris Therapeutics, Inc. (KLRS), a Healthcare sector company. KLRS is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), Kalaris Therapeutics, Inc. reports net income of $-10.9M, free cash flow of $-11.6M. Top institutional holders of KLRS by reported 13-F value include Samsara BioCapital,, RTW INVESTMENTS,, Paradigm Biocapital Advisors, based on the most recent SEC filings. KLRS trades on the Nasdaq exchange and files with the SEC under CIK 1754068. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate KLRS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Kalaris Therapeutics, Inc. directly from SEC EDGAR.
Net Income
Q1 2026
$-10.9M
Free Cash Flow
Q1 2026
$-11.6M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
Net Income
-607.7% YoYOperating Income
-541.2% YoYEPS (Diluted)
Total Assets
+98.7% YoYOp. Cash Flow
-604.8% YoY| Metric | FY 2022 | FY 2019 | FY 2018 |
|---|---|---|---|
| Revenue | — | $165.0K | — |
| Net Income | $-168.7M -607.7% | $-23.8M | — |
| Operating Income | $-171.2M -541.2% | $-26.7M | — |
| EPS (Diluted) | $-2.20 | — | — |
| Total Assets | $277.1M +98.7% | $139.4M | — |
| Operating Cash Flow | $-142.1M -604.8% | $-20.2M | — |
AI Insight: KLRS Ratio Trends
Kalaris Therapeutics remains deeply loss-making with ROA stuck near -40% and no margin data available to identify a path to profitability.
• ROA deteriorated sharply from -13.5% in Q3 2024 to -61.6% in Q4 2024, signaling a significant cash burn acceleration mid-cycle.
• ROE swung from -50.7% in Q4 2025 back to -63.3% in Q1 2026, showing no sustained improvement in returns on equity.
• ROIC hit -92.3% in Q2 2025 before partially recovering to -54.8% in Q4 2025 and -69.0% in Q1 2026 — still deeply negative.
⚠ OpMargin and NPM are entirely absent across all periods — inability to assess revenue or cost structure is a major analytical gap.
⚠ D/E ratio is unavailable throughout; leverage profile is unknown, raising balance sheet transparency concerns for a loss-stage biotech.
⚠ Q2 2025 ROIC of -92.3% was the worst on record — monitor whether Q1 2026's -69.0% represents a durable recovery or temporary relief.
Get alerted when KLRS's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Kalaris Therapeutics, Inc. including:
Top Institutional Holders of KLRS
Samsara BioCapital, LLC
$74.7M12,948,081 shRTW INVESTMENTS, LP
$7.5M1,300,000 shParadigm Biocapital Advisors LP
$4.0M700,000 shAlyeska Investment Group, L.P.
$3.3M572,687 shSiren, L.L.C.
$2.5M435,798 shIkarian Capital, LLC
$2.1M360,000 shPropel Bio Management, LLC
$1.7M295,771 shVANGUARD CAPITAL MANAGEMENT LLC
$1.5M255,348 shKalehua Capital Management LLC
$782.3K135,585 shRAYMOND JAMES FINANCIAL INC
$686.0K118,887 sh
| Fund | Value | Shares |
|---|---|---|
| Samsara BioCapital, LLC | $74.7M | 12,948,081 |
| RTW INVESTMENTS, LP | $7.5M | 1,300,000 |
| Paradigm Biocapital Advisors LP | $4.0M | 700,000 |
| Alyeska Investment Group, L.P. | $3.3M | 572,687 |
| Siren, L.L.C. | $2.5M | 435,798 |
| Ikarian Capital, LLC | $2.1M | 360,000 |
| Propel Bio Management, LLC | $1.7M | 295,771 |
| VANGUARD CAPITAL MANAGEMENT LLC | $1.5M | 255,348 |
| Kalehua Capital Management LLC | $782.3K | 135,585 |
| RAYMOND JAMES FINANCIAL INC | $686.0K | 118,887 |
More Healthcare Companies
View all Healthcare →Put KLRS on your watchlist
Track score changes the day Kalaris Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is KLRS a good stock to buy?
13F Pro's AI-powered analysis of Kalaris Therapeutics, Inc. (KLRS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for KLRS are available on the KLRS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own KLRS?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling KLRS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Kalaris Therapeutics, Inc.'s investment landscape.